Amec Foster Wheeler awarded Pfizer Saudi Arabian contract
• Extension of Greenfield pharmaceutical facility project work
• Contract lengthens Amec Foster Wheeler’s role since 2010
Amec Foster Wheeler announces today that it has been awarded a contract for the commissioning and qualification management for Pfizer Saudi’s Greenfield pharmaceutical manufacturing facility in King Abdullah Economic City (KAEC), in Rabigh, in the Kingdom of Saudi Arabia.
Amec Foster Wheeler’s services will include commissioning management and coordination, and facilitation of the operational qualification protocols.
The award follows Amec Foster Wheeler’s successful completion of engineering services for the facility in partnership with Egyptian engineering company EGEC, which included site master plan, conceptual and basic design, detailed engineering, and support for the selection of a general contractor for the execution of the construction works.
The value of the contract has not been disclosed.
Amec Foster Wheeler (www.amecfw.com) designs, delivers and maintains strategic and complex assets for its customers across the global energy and related sectors.
With pro-forma 2014 annualised scope revenues of £5.5 billion and over 40,000 people in more than 55 countries, the company operates across the whole of the oil and gas industry – from production through to refining, processing and distribution of derivative products – and in the mining, clean energy, power generation, pharma, environment and infrastructure markets.
Amec Foster Wheeler shares are publicly traded on the London Stock Exchange and its American Depositary Shares are traded on the New York Stock Exchange. Both trade under the ticker AMFW.
Pfizer Saudi’s Greenfield pharmaceutical manufacturing facility, King Abdullah Economic City
The new facility, occupying a 32,000 m2 plot, will be dedicated to solid dosage forms, and includes production functions (manufacturing, primary and secondary packaging) as well as support areas (quality control laboratories, warehouse, services, staff support areas).
The new plant is expected to become operational in 2016. Once complete, the facility will produce 18 million pharmaceutical packs per year and a broad range of Pfizer’s medicines currently supplied to the Kingdom of Saudi Arabia.
This announcement contains statements which constitute “forward-looking statements”. Forward-looking statements include any statements related to the timing and success of contracts, and are generally identified by words such as “believe,” “expect,” “anticipate,” “intend,” “estimate,” “will,” “may,” “continue,” “should” and other similar expressions. Forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Amec Foster Wheeler, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking statements.
Amec Foster Wheeler does not undertake to update any of the forward-looking statements after this date to conform such statements to actual results, to reflect the occurrence of anticipated results or otherwise.